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Abstract
Background: Results obtained from brain imaging studies indicate that serotonin transporter
(SERT) and dopamine transporter (DAT) densities are altered in major depression. However, no
such studies have been published on current mania or hypomania.
Case presentation: In this single photon emission computed tomography (SPECT) study with
[123I]nor-β-CIT we present a case with simultaneous symptoms of major depression and
hypomania. She had an elevated serotonin transporter availability (SERT) in the midbrain and
elevated dopamine transporter availability (DAT) in the striatum, which normalised in a one-year
follow-up period during which she received eight months of psychodynamic psychotherapy.
Conclusions: To our knowledge, this is the first report on SERT and DAT associated with mania.
In our case the availability of both SERT in the midbrain and DAT in the striatum were elevated at
baseline and declined during psychotherapy, while the SERT and DAT of the depressed controls
increased during psychotherapy. Symptoms of hypomania in the case were alleviated during
psychotherapy. Clinical recovery was also reflected in the Hamilton Depression Rating Scale
(HDRS) scores.
Background
Decreased serotonin transporter densities (SERT) have
been recorded from the brains of depressed patients [1,2],
which have also been reported to normalise during psy-
chotherapy [3,4]. A few studies have also revealed altered
levels of dopamine transmission in major depression
[5,6]. However, in a search of the PubMed database we
found no serotonin-specific brain imaging studies on
mania or hypomania.
In this paper we present a case with simultaneous symp-
toms of major depression and hypomania. The structural
diagnostic classifications DSM-IV and ICD-10 are unable
Published: 13 September 2004
BMC Psychiatry 2004, 4:27 doi:10.1186/1471-244X-4-27
Received: 16 April 2004
Accepted: 13 September 2004
This article is available from: http://www.biomedcentral.com/1471-244X/4/27
© 2004 Tolmunen et al; licensee BioMed Central Ltd. 
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Psychiatry 2004, 4:27 http://www.biomedcentral.com/1471-244X/4/27
Page 2 of 6
(page number not for citation purposes)
to diagnose this kind of mixed state, even though similar
cases have been presented earlier in the literature [7].
Materials and methods
Case
The index subject was a 25-year-old female with a history
of two periods of major depression according to the DSM-
IV-R criteria. She had also had hypomanic periods that did
not completely fulfil the criteria of mania, and at baseline
she fulfilled the criteria of hypomania, moderate depres-
sion and dysthymia (296.32, 300.40). She was overactive,
restless and irritated and coped with a reduced amount of
sleep. She had difficulty in concentrating on one thing at
a time, and she appeared very lively and talkative. She was
therefore diagnosed with bipolar mood disorder type II.
In other words, our index patient had a mixed mania
without fulfilling the criteria of full-blown mania during
the baseline scan.
Controls
The 6 female depressed controls were diagnosed to have
severe or moderate depression (296.22, 296.23, 296.32 or
296.33). Three of them also fulfilled the criteria for dys-
thymia (300.40) and three had previously suffered peri-
ods of major depression. They were participants of our
larger study on the effects of psychotherapy on SERT and
DAT densities to be reported in full elsewhere.
The group of 10 healthy controls consisted mainly of
employees of Kuopio University Hospital and medical
students. Depression was an exclusion criterion for the
control group. Controls had previously received no psy-
chotropic medication or other psychiatric treatment and
were physically healthy.
Psychiatric evaluation
Psychiatric diagnosis was based on clinical assessment
and verified for all study subjects by a trained independ-
ent psychiatrist using the Structured Clinical Interview for
DSM-IV-R (SCID-I) [8]. The severity of depression was
assessed with the 17-item Hamilton Depression Rating
Scale (HDRS) [9].
Setting, therapist and therapy
The depressed controls (see Table for sociodemographic
characteristics) received psychotherapy for 12 months in
an outpatient clinic of the Department of Psychiatry of
Kuopio University Hospital. The case discontinued the
therapy after eight months because she felt it was no
longer useful to her. The case and the depressed controls
had received no psychiatric treatment or medication prior
the SPECT imaging and they were treated without medica-
tion. Psychotherapy sessions occurred twice a week, 80
sessions per year. The psychotherapists had formal post-
graduate professional training in psychodynamic psycho-
therapy. The study design was approved by the ethics
committee of Kuopio University Hospital.
Participants of the study were right-handed and all were
female. The depressed and the healthy controls were age-
matched with the case (Table). The healthy controls were
not followed up.
Imaging procedure
SPECT imaging was performed on the Wednesday after
the menstrual bleeding that preceded the psychotherapy
and on 12-month follow-up. A dose of 185 MBq of [123I]
nor-β-CIT (supplied by MAP Medical Technologies OY,
Tikkakoski Finland) was diluted in a volume of 10 ml
physiological saline. The specific activity was higher than
1.8 × 1011 Bq/µmol [10]. The dose was slowly injected
into the right antecubital vein in a dimly lit and quiet
room. Serial SPECT scans (5 min, 6 h and 24 h) were per-
formed on a dedicated Siemens MultiSPECT 3 gamma
camera with fan-beam collimators (Siemens Medical Sys-
tems; Hoffman Estates I11., USA) [11]. Head positioning
was monitored during acquisition by using two position
lasers.
Data analysis
The SPECT scans were decay-corrected and reconstructed
with Butterworth-filtered back-projection in a 128 × 128
matrix with a pixel size of 3 × 3 mm, and were attenua-
tion-corrected with Chang's algorithm [10,11]. The imag-
ing resolution was 8–9 mm. The SPECT slices were
consecutively summarised to the slice thickness of 6 mm
and re-aligned using a Siemens semi-automatic brain
quantification program and the Talairach coordinates
[12]. The slices were rotated and re-aligned so that
transaxial (x-direction), sagittal (y-direction) and coronal
(z-direction) slices were at right angles to each other.
Region of interest placement was based on a Siemens
semi-automatic brain quantification program. The lower
threshold of 60% of the maximum count was used to
reduce the volume averaging and partial volume errors.
Regions of interest were the cerebellum, striatum and the
midbrain. It was assumed that the cerebellum (reference
region) corresponds to a two-compartment model
(unbound tracer in arterial blood and free plus non-spe-
cifically bound tracer in the tissue) [13]. The specific bind-
ing in ml/ml for SERT and DAT was calculated using a
graphical plot [13]. The slope of this plot is equal to the
distribution volume ratio: (Region - Cerebellum)/Cere-
bellum = VD - 1. The striatal uptake was pooled.
Functional neuroanatomy by means of SPECT was con-
firmed using magnetic resonance imaging (MRI) within
two weeks of the SPECT imaging. If any cerebral focal
abnormalities or organic brain diseases were detected byBMC Psychiatry 2004, 4:27 http://www.biomedcentral.com/1471-244X/4/27
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MRI scan, the patient was excluded from our study. The
participants of our study thus had normal findings.
Reproducibility of SPECT
The reproducibility of the SPECT scan had been previ-
ously studied with eleven healthy subjects (5 males and 6
females; age range 20–39 y). SPECT studies were per-
formed twice with a 12-month interval. The correspond-
ence between the studies was good, with the mean
difference being 0.00 ± 0.08 (SD = standard deviation) for
SERT (mean and SD: 1.27 ± 0.11 and 1.27 ± 0.14, respec-
tively) and 0.04 ± 0.18 for DAT (mean and SD: 2.49 ± 0.28
and 2.45 ± 0.27, respectively). The intraclass correlation
coefficient was 0.82 (p < 0.01) and 0.79 (p < 0.01), respec-
tively (unpublished data).
Statistics
The Student's t-test was used to compare the depressed
controls and the healthy controls and paired samples t-
test to compare SERT densities of the depressed controls at
baseline and on follow-up. A p-value of less than 0.05 was
considered as the criterion for statistical significance.
Results
The background characteristics of the case and the con-
trols are presented in the table. The case and the depressed
controls had HDRS scores of 14 or more.
The midbrain SERT availability did not correlate with
HDRS scores in depressive controls either at baseline or
on follow-up. Neither did the change in the HDRS score
correlate with changes in SERT or DAT capacities under
therapy.
The case had an elevated SERT availability in the midbrain
at baseline, while the depressed controls had decreased
levels compared to the healthy controls (t = 3.17, p < 0.01;
Table and Figure 1). The SERT availability of the index
case was two standard deviations (SD) higher than the
mean SERT availability of the depressed controls and
almost two SD higher than the mean SERT availability of
the healthy controls. The MRI scans of the case and the
controls were normal. At the twelve-month follow-up, the
HDRS scores of both the case and the depressed controls
had decreased. The mean decrease in HDRS scores in
depressed patients during the follow-up period was 5 (SD
3.3; t = 3.7, p = 0.02). The SERT availability in the mid-
brain had decreased in the case by 9.9% (Fig. 2) and
increased in the depressed controls by 12.5% (t = 3.00, p
= 0.03) during the one year of psychotherapy.
DAT densities in the striatum were elevated in the case
(Table, Fig. 2.) and slightly elevated in the depressed con-
trols at baseline compared to the healthy controls. On 12-
month follow-up the DAT availability in the striatum of
the case had decreased by 5.1%, while DAT densities in
Table 1: Characteristics of the participants. Values of the controls are means ± SD.
Case Depressed controls n = 6 Healthy controls n = 10
Age, y 25 27.2 (5.9) 26.3 (5.9)
Duration of depressive episode, months 9 10.6 (6.9) -
SERT availability in midbrain at baseline 1.51 1.08 (0.12) 1.28 (0.12)
SERT availability in midbrain at 12 months 1.36 1.23 (0.20) -
DAT availability in striatum at baseline 2.75 2.48 (0.35) 2.45 (0.25)
DAT availability in striatum at 12 months 2.61 2.70 (0.45) -
HDRS score at baseline 15 17.67 (3.44) -
HDRS score at 12 months 5 12.66 (5.09) -
Abbreviations: DAT: Dopamine transporter, HDRS: Hamilton Depression Rating Scale SD: Standard deviation, SERT: Serotonin transporter.
SERT densities of the healthy controls, depressed controls  and of the index subject at baseline Figure 1
SERT densities of the healthy controls, depressed controls 
and of the index subject at baseline.
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the depressed controls had increased by 8.8%. The
increase in DAT binding was not significant (data not
shown).
Discussion
To our knowledge, this is the first report on SERT and DAT
associated with a current mania. In our case the densities
of both SERT in the midbrain and DAT in the striatum
were elevated at baseline and they decreased during
Transaxial slices of [123I]nor-β-CIT scans in the index subject at baseline (A and B) and after 12 months (C and D) Figure 2
Transaxial slices of [123I]nor-β-CIT scans in the index subject at baseline (A and B) and after 12 months (C and D). A and C 
indicate midbrain SERT binding and B and D striatal DAT binding. A 10% step colour scale is shown on the right and the cere-
bellum was used in its normalization.BMC Psychiatry 2004, 4:27 http://www.biomedcentral.com/1471-244X/4/27
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psychotherapy, while the SERT and DAT of the depressed
controls increased during psychotherapy. Clinical recov-
ery was also reflected in the change in the HDRS score.
Furthermore, the index case had no symptoms of hypo-
mania after the psychotherapy.
Ichimiya et al. [14] found increased SERT binding of the
radioligand in the thalamus in a sample of patients with
either major depression (n = 7) or bipolar disorder (n = 6)
compared to healthy controls (n = 21). In their study the
bipolar patients were either depressed or euthymic prior
to brain imaging. There were no significant differences in
binding potentials in the midbrain compared to the
mood-disorder patients and the healthy controls. Bipolar
patients had slightly higher binding potentials in the mid-
brain than the healthy controls, while patients with major
depression had slightly lower binding potentials than the
healthy controls. However, these differences were not sig-
nificant. The patients of Ichimiya and co-workers were
euthymic or depressed, so we cannot compare our results
with theirs.
It is clinically well known that anti-depressive medication,
including serotonin-selective drugs, may aggravate mania
[15]. If the serotonergic functions had already been ele-
vated in mania and had then been further enhanced by
anti-depressive medication, it is reasonable that this
might further increase the manic symptoms.
In animal models, the administration of an amino-acid
mixture lacking the cathecolamine precursors tyrosine
and phenylalanine decreases the availability of plasma
tyrosine to the brain, which further diminishes
cathecolamine synthesis [16]. In a few clinical human
studies, decreasing tyrosine availability has had a positive
effect on the symptoms of acute mania [17,18]. Tyrosine
depletion has also led to decreased dopamine functions in
healthy volunteers [19]. In positron emission tomogra-
phy, a tyrosine-free amino-acid mixture increased striatal
binding of the dopamine receptor ligand in healthy vol-
unteers, which may reflect lowered presynaptic dopamine
release [20]. SPECT studies revealing increased ampheta-
mine-induced dopamine release in bipolar disorder
patients have also been published [21]. The above-men-
tioned results indicate that acute mania may be associated
with elevated dopaminergic functions in the central nerv-
ous system. A decrease in the DAT availability of the stria-
tum was associated with clinical recovery in our case,
which may support this hypothesis.
The DAT densities of the depressed controls were only
slightly above the level of the healthy controls. Laasonen-
Balk et al. [5] have previously observed a greater increase
in DAT densities in depressed patients. Because of the
small sample size of this study there was insufficient sta-
tistical power to draw any conclusions in this issue. Our
results support previous findings that the SERT densities
of depressed patients are lower than in healthy controls
[1,2,4]. Previous studies on neurotransmitters in associa-
tion with mania have mostly dealt with dopamine.
We cannot completely rule out the bias of nor-β-cit bind-
ing to the noradrenergic transporters (NORT). The
noradrenergic cell-body rich nucleus ceruleus is close to
our target region. This is assumed to contain the nucleus
raphe, which is mostly comprised of serotonergic cell-
bodies. The dopamine cell-body rich substantia nigra is
also located close to our region of interest. However, nor-
β-cit is considered to be more serotonin-specific than pre-
vious radioligands [10].
Three studies have been published on the association
between SERT availability and the serotonin transporter
genotype. Two of these were performed on healthy sub-
jects [22,23], while the third concerned abstinent alcohol-
ics and healthy controls [24]. In the study of Van Dyck
and co-workers the short homozygotes had a significantly
greater SERT availability than the long-short heterozy-
gotes, which indicates a complex relationship between the
genotype and SERT availability. Furlong et al. [25] found
an association between promoter allele 2 of the SERT gene
and bipolar disorder. Studies combining brain imaging
and data of genotype are also recommended in the evalu-
ation of bipolar disorder. PET would be a more valid
method if adequate radioligands were available [14], as
PET provides absolute rather than relative values for trans-
porter availability.
Conclusion
We have found no previous imaging studies showing that
serotonin plays a role in mania. Further research is needed
to determine whether our findings could be generalised to
all manic states.
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